UNSPSC 51334417: Tenilapine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0U312O2BE. European Medicines Agency schedules Tenilapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10892MIG. Tenilapine generally arises in the molecular formula C17H16N4S2.

UNSPSC 51334417 Tenilapine is a Commodity code that does not map clearly to the recent state and local procurement activity tagged under it. The three most recent opportunities—Seminole County's procurement for naloxone and drug deactivation systems, Texas HHS's request for information on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products—involve naloxone, prescription fulfillment intermediation, and wholesale generic pharmaceuticals respectively, none of which align with tenilapine (a cardiac glycoside medication) as a specific procurement focus. State and local health agencies, cooperative purchasing alliances, and county health departments do solicit pharmaceutical products and healthcare supplies through this taxonomy, but the recent tagged opportunities show little targeted demand for tenilapine itself.

Issuing bodies include county health systems (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing consortiums (MMCAP, administered by Minnesota). Geographic activity appears concentrated in Florida, Texas, and the upper Midwest, with MMCAP participation extending to Oregon. The Seminole County IFB (response due July 26, 2023) sought naloxone and drug deactivation systems on a quarterly delivery schedule; the Texas HHS RFI (posted April 3, 2026) explored direct-to-manufacturer prescription strategies; and the MMCAP RFP (proposals due March 26, 2026) established multi-award contracts for generic pharmaceuticals through authorized wholesalers effective July 1, 2026. If pursuing work in cardiac or pharmaceutical commodities under this code, verify with issuing bodies that tenilapine is actively specified in their procurement needs, as current tagged activity does not demonstrate regular demand.